CohBar, Inc. (CWBR)

NASDAQ: CWBR · IEX Real-Time Price · USD
0.199
-0.006 (-3.17%)
At close: May 16, 2022 4:00 PM
0.208
0.010 (4.987%)
After-hours:May 16, 2022 7:37 PM EDT
Market Cap17.27M
Revenue (ttm)n/a
Net Income (ttm)-15.48M
Shares Out86.98M
EPS (ttm)-0.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume309,626
Open0.202
Previous Close0.205
Day's Range0.198 - 0.210
52-Week Range0.180 - 2.270
Beta2.55
AnalystsBuy
Price Target2.93 (+1,376.1%)
Earnings DateMay 16, 2022

About CWBR

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide...

IndustryBiotechnology
Founded2007
Employees9
Stock ExchangeNASDAQ
Ticker SymbolCWBR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for CWBR stock is "Buy." The 12-month stock price forecast is 2.93, which is an increase of 1,376.07% from the latest price.

Price Target
$2.93
(1,376.07% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CohBar Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress

Conference call and webcast today at 5:00 p.m. ET, May 16, 2022 Conference call and webcast today at 5:00 p.m. ET, May 16, 2022

7 hours ago - GlobeNewsWire

CohBar Announces Extension of Nasdaq Compliance Period and Summarizes 2022 Annual Meeting Proposal

MENLO PARK, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded...

4 days ago - GlobeNewsWire

CohBar to Announce 2022 First Quarter Financial Results and Provide Business Update on May 16, 2022

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

2 weeks ago - GlobeNewsWire

CohBar Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Conference call and webcast at 5:00 p.m. ET today, March 29, 2022 Conference call and webcast at 5:00 p.m. ET today, March 29, 2022

1 month ago - GlobeNewsWire

CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

2 months ago - GlobeNewsWire

CohBar to Present at H.C. Wainwright BIOCONNECT Conference

MENLO PARK, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome ...

4 months ago - GlobeNewsWire

7 of the Best Penny Stocks Under $3 for 2022 to Buy Now

Penny stocks under $3 are full of potential and potential pitfalls. These are relatively safe and worth your consideration.

4 months ago - InvestorPlace

CohBar Announces Changes to its Board of Directors and R&D Leadership

Founding board members transition to reconstituted Scientific Advisory Board

4 months ago - GlobeNewsWire

CohBar's CEO to Participate in Upcoming BIO Webinar

MENLO PARK, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

5 months ago - GlobeNewsWire

7 Penny Stocks With the Potential to 10X in 2022

The broader market looks expensive, but these penny stocks provide low-cost opportunities for considerable upside according to analysts. The post 7 Penny Stocks With the Potential to 10X in 2022 appeare...

Other symbols:CBAYPAYSSENSSOLOSRGA
5 months ago - InvestorPlace

CohBar Reports Third Quarter 2021 Financial Results and Provides Business Update

Company to host conference call at 5:00 p.m. ET

6 months ago - GlobeNewsWire

5 Top Penny Stocks To Watch Under $1 After CSCW Stock Explodes

There are so many traders looking for the best penny stocks 2021… The post 5 Top Penny Stocks To Watch Under $1 After CSCW Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Informati...

Other symbols:AIKIBHATGTEOGEN
6 months ago - PennyStocks

CohBar to Announce 2021 Third Quarter Financial Results and Provide Business Update on November 15, 2021

Company to host conference call at 5:00 p.m. ET Company to host conference call at 5:00 p.m. ET

6 months ago - GlobeNewsWire

CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants

MENLO PARK, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic dise...

6 months ago - GlobeNewsWire

CohBar Announces Proposed Public Offering of Common Stock and Warrants

MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic dise...

6 months ago - GlobeNewsWire

CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021

MENLO PARK, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

7 months ago - GlobeNewsWire

CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference

MENLO PARK, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

7 months ago - GlobeNewsWire

CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors

MENLO PARK, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend...

8 months ago - GlobeNewsWire

CohBar Granted U.S. Patent Covering CB4211 Compositions and Use for Treating Nonalcoholic Steatohepatitis (NASH)

MENLO PARK, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend...

8 months ago - GlobeNewsWire

CohBar Appoints Carol Nast to Its Board of Directors

MENLO PARK, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

9 months ago - GlobeNewsWire

CohBar Reports Second Quarter 2021 Financial Results and Provides Business Update

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

9 months ago - GlobeNewsWire

CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity

MENLO PARK, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

9 months ago - GlobeNewsWire

CohBar Stock Slumps As Data From NASH, Obesity Candidate Delayed By Almost Two Months

CohBar Inc (NASDAQ: CWBR) has updated the timing for releasing Phase 1a/1b trial data of CB4211 for the potential treatment of nonalcoholic steatohepatitis (NASH) and obesity.  The process of data entry...

10 months ago - Benzinga

CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity

MENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

10 months ago - GlobeNewsWire

CohBar to Present at the BIO 2021 Digital Conference

MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

11 months ago - GlobeNewsWire